This site is intended for Healthcare professionals only.

Lilly revenue rises 7.2 pct on higher demand for new drugs

Lilly revenue rises 7.2 pct on higher demand for new drugs

Eli Lilly and Co reported a 7.2 percent rise in quarterly revenue, lifted by higher demand for its diabetes drug Trulicity and other new treatments.

The drugmaker said net income rose to $771.8 million, or 73 cents per share, in the fourth quarter ended Dec. 31, from $478.4 million, or 45 cents per share, a year earlier.

Revenue rose to $5.76 billion from $5.38 billion.

Source: Reuters
0 comment(s) on Lilly revenue rises 7.2 pct on higher demand for new drugs

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted